Ketamine News & Research
An open label study which treated subjects with a series of up to six intravenous ketamine infusions for depression following a wash out period from antidepressants. It showed a 71% success rate in treating depressive symptoms with a median time to relapse of 18 days, with the 24th and 75th percentile being 11 and 27 days respectively.
An open label study of repeat intravenous ketamine infusions for depression, that did not require stopping the current antidepressant medications. The study showed repeated ketamine infusions increased antidepressant response and remission rates compared to a single infusion, response and remission were achieved without washout from previous antidepressants, the trajectory of response and remission varied by subjects during ketamine infusions, and durability of antidepressant response after completing six infusions was highly variable.
Chronic Pain Effect
Complex regional pain syndrome: An optimistic perspective.
Chronic Migraine Effect
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series